Published in Expert Opin Pharmacother on November 01, 2007
HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin Cancer Res (2011) 1.06
ING proteins as potential anticancer drug targets. Curr Drug Targets (2009) 0.87
Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop. Am J Hematol (2011) 0.75
Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm (2003) 3.34
Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care (2003) 2.33
Costs of necrotizing enterocolitis and cost-effectiveness of exclusively human milk-based products in feeding extremely premature infants. Breastfeed Med (2011) 2.12
Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics (2007) 1.87
Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis (2004) 1.65
Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues. Bioconjug Chem (2003) 1.58
Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opin (2004) 1.50
Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure. Cardiovasc Drugs Ther (2004) 1.46
Where's the value in health care? Value Health (2006) 1.45
Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract (2002) 1.45
Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II. Value Health (2009) 1.43
Patterns of clinical management of atopic dermatitis in infants and toddlers: a survey of three physician specialties in the United States. J Pediatr (2013) 1.39
Needlestick injuries in the United States. Epidemiologic, economic, and quality of life issues. AAOHN J (2005) 1.37
Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature. J Manag Care Pharm (2006) 1.26
177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med (2006) 1.23
Economic burden of acute myeloid leukemia: a literature review. Cancer Treat Rev (2004) 1.12
Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI. Value Health (2009) 1.11
Cost-effectiveness analysis of pharmaceutical care in a medicare drug benefit program. Value Health (2003) 1.09
Evaluating the cost-effectiveness of statins. J Manag Care Pharm (2004) 1.08
Short- and long-term effects of acute myeloid leukemia on patient health-related quality of life. Cancer Treat Rev (2004) 1.06
Chronic lymphocytic leukemia: economic burden and quality of life: literature review. Am J Ther (2005) 1.06
Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin (2010) 1.01
Economic burden of head and neck cancer. A literature review. Eur J Health Econ (2004) 1.01
Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C. Expert Rev Pharmacoecon Outcomes Res (2012) 1.01
Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes. BMC Infect Dis (2013) 0.99
Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3. Gynecol Oncol (2011) 0.98
Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV. Value Health (2009) 0.98
Where do I send thee? Does physician-ownership affect referral patterns to ambulatory surgery centers? Health Aff (Millwood) (2008) 0.98
Huaier aqueous extract inhibits ovarian cancer cell motility via the AKT/GSK3β/β-catenin pathway. PLoS One (2013) 0.96
Understanding the underlying drivers of inpatient cost growth: a literature review. Am J Manag Care (2003) 0.96
Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report--Part III. Value Health (2009) 0.96
Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective: the ISPOR Drug Cost Task Force report--Part V. Value Health (2009) 0.96
Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC Cancer (2012) 0.96
Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health (2003) 0.95
177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression. J Nucl Med (2009) 0.92
Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer. Int J Oncol (2008) 0.92
Antitumor and immunomodulatory activity of a water-soluble low molecular weight polysaccharide from Schisandra chinensis (Turcz.) Baill. Food Chem Toxicol (2013) 0.91
Effects of ambulatory-care pharmacist consultation on mortality and hospitalization. Am J Manag Care (2003) 0.91
Estrogen and progestin regulate HIF-1alpha expression in ovarian cancer cell lines via the activation of Akt signaling transduction pathway. Oncol Rep (2009) 0.91
Combined use of biomarkers for detection of ovarian cancer in high-risk women. Tumour Biol (2010) 0.90
Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors. Curr Med Res Opin (2006) 0.90
Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T₁₋₂N₀M₀ breast cancer. Pol J Pathol (2013) 0.89
Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer. Expert Rev Pharmacoecon Outcomes Res (2012) 0.89
Clinicopathological risk factors for pelvic lymph node metastasis in clinical early-stage endometrioid endometrial adenocarcinoma. Int J Gynecol Cancer (2012) 0.89
Needlestick injury in acute care nurses caring for patients with diabetes mellitus: a retrospective study. Curr Med Res Opin (2005) 0.89
The burden and outcomes associated with four leukemias: AML, ALL, CLL and CML. Expert Rev Anticancer Ther (2003) 0.88
Long term healthcare costs of infants who survived neonatal necrotizing enterocolitis: a retrospective longitudinal study among infants enrolled in Texas Medicaid. BMC Pediatr (2013) 0.88
Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia. Sleep (2009) 0.88
Antidepressant use in geriatric populations: the burden of side effects and interactions and their impact on adherence and costs. Am J Geriatr Psychiatry (2011) 0.87
Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours. Clin Drug Investig (2007) 0.87
Transmission-dynamic model to capture the indirect effects of infant vaccination with Prevnar (7-valent pneumococcal conjugate vaccine (PCV7)) in older populations. Vaccine (2009) 0.87
The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States. Neuro Oncol (2013) 0.87
Osteoprotegerin/RANK/RANKL axis in cardiac remodeling due to immuno-inflammatory myocardial disease. Exp Mol Pathol (2008) 0.86
Perioperative myocardial ischemic injury in high-risk vascular surgery patients: incidence and clinical significance in a prospective clinical trial. J Vasc Surg (2006) 0.86
US hospital database analysis of invasive aspergillosis in the chronic obstructive pulmonary disease non-traditional host. J Med Econ (2011) 0.86
Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensity-score and instrumental variable methods to adjust for treatment-selection bias. Pharmacoepidemiol Drug Saf (2012) 0.85
Costs and benefits of male circumcision. JAMA Pediatr (2013) 0.85
The impact of drinking and drinking consequences on short-term employment outcomes in at-risk drinkers in six southern states. J Behav Health Serv Res (2002) 0.84
Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling. Curr Med Res Opin (2008) 0.84
[Four surgical patterns of hysterectomy for uterine without prolapsis: a clinical study]. Zhonghua Yi Xue Za Zhi (2002) 0.84
In vitro and in vivo metabolism of Lu-AMBA, a GRP-receptor binding compound, and the synthesis and characterization of its metabolites. Bioconjug Chem (2009) 0.84
Estimating preference-based EQ-5D health state utilities or item responses from neuropathic pain scores. Patient (2012) 0.83
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis. J Med Econ (2012) 0.83
Asthma costs and utilization in a managed care organization. J Allergy Clin Immunol (2008) 0.83
Economic impacts attributable to the early clinical benefit of atorvastatin therapy--a US managed care perspective. Curr Med Res Opin (2007) 0.83
Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. Clin Ther (2003) 0.83
Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison. Int J Gynecol Cancer (2015) 0.83
Epidemiology and clinical burden of acute myeloid leukemia. Expert Rev Anticancer Ther (2003) 0.81
A protein profile study to discriminate CIN lesions from normal cervical epithelium. Cell Oncol (Dordr) (2011) 0.81
Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. Pharmacoeconomics (2005) 0.80
Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States. Pharmacoeconomics (2013) 0.80
Biomarkers and microsatellite instability analysis of curettings can predict the behavior of FIGO stage I endometrial endometrioid adenocarcinoma. Mod Pathol (2011) 0.80
Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer. Clin Ther (2012) 0.80
The prognostic value of the orphan nuclear receptor DAX-1 (NROB1) in node-negative breast cancer. Anticancer Res (2011) 0.80
Economic evaluations of novel antipsychotic medications: a literature review. Schizophr Res (2003) 0.80
Appropriate econometric methods for pharmacoeconometric studies of retrospective claims data: an introductory guide. J Manag Care Pharm (2005) 0.79
Facile preparation of lightweight microcellular polyetherimide/graphene composite foams for electromagnetic interference shielding. ACS Appl Mater Interfaces (2013) 0.79
"Turn-on" fluorescence detection of lead ions based on accelerated leaching of gold nanoparticles on the surface of graphene. ACS Appl Mater Interfaces (2012) 0.79
Comparing anti-hyperglycemic activity and acute oral toxicity of three different trivalent chromium complexes in mice. Food Chem Toxicol (2012) 0.79
Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis. Expert Rev Pharmacoecon Outcomes Res (2015) 0.79
Cost-benefit analysis of in-hospital influenza vaccination of postpartum women. Obstet Gynecol (2012) 0.78
Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. Cancer (2009) 0.78
Mapping of the Insomnia Severity Index and other sleep measures to EuroQol EQ-5D health state utilities. Health Qual Life Outcomes (2011) 0.78
Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP). Value Health (2010) 0.78
Portable paper-based device for quantitative colorimetric assays relying on light reflectance principle. Electrophoresis (2014) 0.78
Molecular biomarkers in endometrial hyperplasias predict cancer progression. Am J Obstet Gynecol (2011) 0.78
Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents. J Med Econ (2012) 0.77
Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours. Pharmacoeconomics (2012) 0.77
High frequency microsatellite instability has a prognostic value in endometrial endometrioid adenocarcinoma, but only in FIGO stage 1 cases. Cell Oncol (Dordr) (2011) 0.77